Reducing ICI dose frequency in cancer patients led to more deaths, prompting early trial termination and highlighting risks of less frequent dosing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results